Send to

Choose Destination
Expert Rev Anticancer Ther. 2010 Sep;10(9):1407-18. doi: 10.1586/era.10.112.

Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.

Author information

Developmental Therapeutics Program, Institute for Pediatric Clinical Research, Children's Hospital Los Angeles, MS#57, Los Angeles, CA 90027, USA.


Spleen tyrosine kinase (SYK) has emerged as a potential molecular target for the treatment of B-lineage leukemias and lymphomas. Here, we provide an overview of the current state of knowledge regarding the regulatory signaling function of SYK and its role in the pathogenesis of B-lineage lymphoid malignancies, available methods and drug candidates for targeting SYK, as well as compelling preclinical and clinical evidence regarding the clinical potential of inhibiting SYK. The further development of rationally designed SYK inhibitors may provide the foundation for therapeutic innovation against B-lineage leukemias and lymphomas.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center